Topics:

Consensus Guidelines Recommend HPV Testing After Borderline Pap Test Results

Consensus Guidelines Recommend HPV Testing After Borderline Pap Test Results

New clinical practice guidelines, published in a recent
issue of the Journal of the American Medical Association (287:2120-2129, 2002),
recommend that women who receive borderline Papanicolaou (Pap) test results
designated as atypical squamous cells of undetermined significance (ASCUS)—a
finding in more than 2 million American women each year—undergo testing
for human papillomavirus (HPV). In clinical studies, HPV has been shown to be
the primary causal factor in the development of cervical cancer.

The new "2001 Consensus Guidelines" were sponsored by the American
Society for Colposcopy and Cervical Pathology (ASCCP) and developed with input
from 29 medical organizations, including the National Cancer Institute, the
Centers for Disease Control and Prevention, and the American Cancer Society.
They represent the first evidence-based, national practice guidelines to offer
doctors, nurses, and other clinicians direction in the management of women with
abnormal Pap test results.

The Preferred Approach

The new consensus guidelines state that HPV testing is the preferred approach
to the management of women with ASCUS Pap results, when it can be performed
directly from a liquid-based Pap test ("reflex" HPV testing) or when
the HPV test specimen can be collected during the initial office visit.
According to the consensus guidelines, "Reflex HPV DNA testing offers
significant advantages since women do not need an additional clinical
examination for specimen collection, and 40% to 60% of women will be spared a
colposcopic examination. Moreover, women testing negative for HPV DNA can
rapidly be assured that they do not have a significant lesion."

Digene Corporation’s Hybrid Capture 2 (hc2) assay has been approved by the
FDA to test for HPV. This HPV test can be performed directly from Cytyc
Corporation’s Thin Prep Pap Test, a liquid-based replacement for the
conventional Pap test.

Evan Jones, chairman and chief executive officer of the Digene Corporation,
said, "These consensus guidelines are a significant new milestone for HPV
testing and cervical cancer screening. They were developed with input from many
of the country’s leading medical organizations involved in women’s health
care and are based on the most recent clinical data demonstrating the
effectiveness of HPV testing in cervical cancer screening. We believe these new
guidelines will further increase adoption of our hc2 HPV test, making it the
standard of care and ensuring that more women have access to the most advanced
cervical cancer screening technology available."

The ALTS Study

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.